Gemcitabine 200 Mg Rtu Fresenius 200 mg, 1 g, 2 g Concentrate for solution for infusion
PDF Leaflet Revision Date: 30 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including NSCLC, pancreatic, bladder, breast, and ovarian cancers.
Dosage (summary)
1,000 mg/mu00b2 IV infusion weekly for NSCLC and pancreatic cancer; 1,250 mg/mu00b2 for bladder cancer.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Not established; avoid in pregnancy and breastfeeding.
Key Drug Interactions
- Cisplatin
- Paclitaxel
- Radiotherapy
Contraindications
- Hypersensitivity to gemcitabine
- Pregnancy
- Breastfeeding
- Children
Common side effects
- Nausea
- Vomiting
- Leucopenia
- Thrombocytopenia
- Allergic skin rash
Counselling Points
- Monitor for signs of toxicity
- Avoid pregnancy during treatment
- Inform about potential skin reactions
Serious warnings
- Haematological toxicity
- Capillary leak syndrome
- Pulmonary toxicity
- Posterior reversible encephalopathy syndrome
Important Disclaimer
The Gemcitabine 200 Mg Rtu Fresenius 200 mg, 1 g, 2 g Concentrate for solution for infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
